Key Developments: Abaxis Inc (ABAX.OQ)

ABAX.OQ on NASDAQ Stock Exchange Global Select Market

47.80USD
29 Aug 2014
Price Change (% chg)

$0.74 (+1.57%)
Prev Close
$47.16
Open
$47.19
Day's High
$47.89
Day's Low
$47.19
Volume
19,101
Avg. Vol
55,727
52-wk High
$48.41
52-wk Low
$32.11

Search Stocks

Latest Key Developments (Source: Significant Developments)

Abaxis Inc declares quarterly dividend
Thursday, 24 Jul 2014 04:01pm EDT 

Abaxis Inc:Declares a quarterly dividend of $0.10 per common share to be paid on Sept. 17, to all shareholders of record as of the close of business on Sept. 3.  Full Article

Abaxis Inc announces USDA approval of VetScan Canine Ehrlichia Antibody Test Kit
Tuesday, 1 Jul 2014 08:00am EDT 

Abaxis Inc:Says Center for Veterinary Biologicals of the U.S. Department of Agriculture (USDA) has approved its VetScan Canine Ehrlichia Antibody Test Kit for use in rapid detection of canine Ehrlichia.Each test can be purchased on an individual basis so that each practitioner has the flexibility to decide which tests to use based on such factors as history and presentation of patient as well as incidence of particular disease in his or her geographic area.  Full Article

Abaxis Inc and VCA Antech Inc announces long term product supply agreement and co marketing agreement
Monday, 12 May 2014 06:30pm EDT 

Abaxis Inc and VCA Antech Inc:Says that they have entered into two long term agreements.The first a long-term product supply agreement for VCA's Animal Hospitals.The second a co-marketing agreement with VCA's Antech Diagnostic reference laboratories.Under the long term product supply agreement VCA will purchase VetScan VS2 chemistry analyzers and diagnostic reagent discs from Abaxis for placement in the majority of VCA's more than 600 animal hospitals located in North America.Additionally, VCA and Abaxis have entered into a non-exclusive co-marketing relationship to capitalize on new growth opportunities within the animal healthcare industry.  Full Article

Abaxis Inc declares quarterly cash dividend
Thursday, 24 Apr 2014 04:00pm EDT 

Abaxis Inc:Declares a quarterly dividend of $0.10 per common share.Payable on June 17, to all shareholders of record as of the close of business on June 3.  Full Article

Abaxis Inc receives health Canada class III approval for Piccolo Xpress
Tuesday, 8 Apr 2014 08:00am EDT 

Abaxis Inc:Health Canada approved Piccolo Xpress and Piccolo Reagent Discs as Class III medical device for use throughout Canada.  Full Article

Abaxis Inc And LamdaGen Corporation Enters Into R&D Diagnostic Collaboration
Friday, 25 Oct 2013 08:00am EDT 

Abaxis Inc and privately-held LamdaGen Corporation announced an R&D agreement to integrate LamdaGen's high-sensitivity Plasmonic ELISA technology on the Abaxis Piccolo and VetScan rotors. System feasibility testing is underway. LamdaGen's patented biosensor platform is based upon LSPR (Localized Surface Plasmon Resonance) and provides rapid, quantitative diagnostic results with broad dynamic range and detection levels in the femtomolar range.  Full Article

Abaxis Inc Declares Special Cash Dividend Of $1.00 Per Share
Thursday, 6 Dec 2012 05:23pm EST 

Abaxis Inc announced that its Board of Directors declared a special cash dividend of $1.00 per share on its outstanding common stock. The dividend will be payable on December 28, 2012 to all shareholders of record at the close of business on December 17, 2012.  Full Article

Abaxis Inc Announces Exclusive Distribution Agreement With Abbott
Wednesday, 31 Oct 2012 05:00am EDT 

Abaxis Inc announced that it has signed an exclusive multi-year distribution agreement with Abbott's Point of Care business to market and distribute the Piccolo Xpress, a portable clinical chemistry system and its full line of one-time use reagent discs to the human medical market. Under terms of the agreement, Abbott will have the exclusive right to distribute and sell in the U.S. and China (including Hong Kong) Abaxis' Piccolo Xpress chemistry analyzer and associated consumables in the professionally attended human healthcare market. Abaxis will retain the distribution rights to current customer, Catapult Health and certain segments including pharmacy and retail store clinics, shopping malls, contract research organizations (CROs), and cruise ship lines. Abaxis will provide technical support and warranty services to support Abbott's commercial efforts.  Full Article

Buffalo fund wrangles small-caps far from Wall Street

NEW YORK - Some of the best fund managers you've never heard of sit in a non-descript office park in Shawnee Mission, Kansas, 1,200 miles from Wall Street. | Video

Search Stocks